Discover Biotech Digital Health Pharma FDA & EMA ONCOLife Contact

ONCOLife Issues

Issue 1

Issue 2

Issue 3

ONCOLife Articles

KEYTRUDA Shows Promising Survival Benefits in Gastric Cancer: Phase 3 Trial

2 May 2024

Merck announced that its KEYNOTE-811 trial of KEYTRUDA® in combination with chemotherapy met its primary goal, significantly improving survival rates for patients with advanced HER2-positive gastric cancer....

FDA Approves Alecensa for ALK+ Lung Cancer Following 76% Drop in Risk of Death

ONCOLife | 19 April 2024

Dr. Redkar Unveils the Role of Targeted and Histology-Agnostic Therapies in Cancer

ONCOLife | 5 April 2024

The Role of Psychedelic-Assisted Therapy in Transforming Cancer Care

ONCOLife | 5 April 2024

Dr. Johan Baeck Discusses PT-112: A New Frontier in Immuno-Oncology

ONCOLife | 15 February 2024

Christine Roth Unveils Bayer Oncology’s Plan for the Next Ten Years

ONCOLife | 15 February 2024

The V Foundation’s Role in Advancing Cancer Research and Supporting Women Scientists

Oncolytic TILT-123 and KEYTRUDA Combination Shows Promise for Ovarian Cancer

ONCOLife

11 April 2024

FDA Approves Carvykti as Targeted CAR-T Cell Therapy for Multiple Myeloma

ONCOLife

6 April 2024

FDA Grants Fast-Track Approval to Enhertu for Treatment of HER2+ Solid Tumors

ONCOLife

5 April 2024

FDA Approves Groundbreaking CAR T Cell Therapy, Abecma, for Multiple Myeloma

ONCOLife

6 April 2024


About Image

About ONCOLife

ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is dedicated to covering key developments in the field of oncology. We delve into the stories behind significant clinical research and drug developments, highlight the latest news, and offer exclusive interviews.